StreetInsider.com News Articles

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)-- Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

Tue, 21 Jul 2026 03:00:00 -0400

Approval expands the approved indication for Crysvita to include infants from 1 month to 1 year of age, enabling earlier intervention in a rare, progressive disease that can impact skeletal development from infancy.
Approval applies across the European Union and European Economic Area, expanding access to treatment for the youngest patients living with XLH.